Healio flags regenerative retina progress

- A panel at Eyecelerator@ARVO discussed regenerative therapies for retinal disease, saying they may be moving from distant promise toward nearer-term clinical readiness. - Panelists singled out approval and access as the main hurdles and urged building referral pathways and early candidate identification over the next 3–6 months. - The coverage is a directional signal rather than new trial evidence; Healio reported on the Eyecelerator panel. (healio.com)